Role of T cells in cancer immunotherapy: Opportunities and challenges

Ahmed, H.; Mahmud, Aar Rafi; Siddiquee, Mohd. Faijanur - Rob –; Shahriar, Asif; Biswas, Partha; Shimul, Md. Ebrahim Khalil; Ahmed, Shahlaa Zernaz; Ema, Tanzila Ismail; Rahman, Nova; Khan, Arif; Mizan, Md. Furkanur Rahaman; Emran, Talha Bin

doi:10.1016/j.cpt.2022.12.002

Cited by 39 publications

(20 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The in silico drug design approach has been becoming increasingly popular in recent times because of its proven potential to accelerate the discovery of safe and effective new medications [ 60 , 61 , 62 ]. This is accomplished through the evaluation of the outcomes of pharmacophore screening, molecular docking, analysis of post-docking interaction, molecular dynamic simulation (MDS), and prediction of noble and effective drug compounds against a higher range of diseases in a computer-simulated environment [ 63 , 64 , 65 ]. In silico drug design can be used to speed up the development of quality drugs by evaluating the outcomes of these processes [ 14 , 49 ].…”

Section: Discussionmentioning

confidence: 99%

Study of MDM2 as Prognostic Biomarker in Brain-LGG Cancer and Bioactive Phytochemicals Inhibit the p53-MDM2 Pathway: A Computational Drug Development Approach

Biswas¹,

Bibi

Yousafi

et al. 2023

Molecules

View full text Add to dashboard Cite

An evaluation of the expression and predictive significance of the MDM2 gene in brain lower-grade glioma (LGG) cancer was carried out using onco-informatics pipelines. Several transcriptome servers were used to measure the differential expression of the targeted MDM2 gene and search mutations and copy number variations. GENT2, Gene Expression Profiling Interactive Analysis, Onco-Lnc, and PrognoScan were used to figure out the survival rate of LGG cancer patients. The protein–protein interaction networks between MDM2 gene and its co-expressed genes were constructed by Gene-MANIA tool. Identified bioactive phytochemicals were evaluated through molecular docking using Schrödinger Suite Software, with the MDM2 (PDB ID: 1RV1) target. Protein–ligand interactions were observed with key residues of the macromolecular target. A molecular dynamics simulation of the novel bioactive compounds with the targeted protein was performed. Phytochemicals targeting MDM2 protein, such as Taxifolin and (-)-Epicatechin, have been shown with more highly stable results as compared to the control drug, and hence, concluded that phytochemicals with bioactive potential might be alternative therapeutic options for the management of LGG patients. Our once informatics-based designed pipeline has indicated that the MDM2 gene may have been a predictive biomarker for LGG cancer and selected phytochemicals possessed outstanding interaction results within the macromolecular target’s active site after utilizing in silico approaches. In vitro and in vivo experiments are recommended to confirm these outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Study of MDM2 as Prognostic Biomarker in Brain-LGG Cancer and Bioactive Phytochemicals Inhibit the p53-MDM2 Pathway: A Computational Drug Development Approach

Biswas¹,

Bibi

Yousafi

et al. 2023

Molecules

View full text Add to dashboard Cite

show abstract

“…Immunotherapies are widely used in the treatment of various cancers, including lung cancer. These treatments primarily involve targeting inhibition of immune checkpoint receptors on T lymphocytes to enhance the immune response against cancer cells 18 . However, despite significant treatments, effectively treating cancer remains a challenging task.…”

Section: Discussionmentioning

confidence: 99%

The importance of alterations in innate lymphoid cell subsets in patients with non-small cell lung cancer and their role in tumorigenesis

CIKMAN,

ÇETİN AKTAŞ,

GELMEZ

et al. 2023

J Cukurova Anesth Surg

View full text Add to dashboard Cite

Objective. Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer-related morbidity and mortality. Diverse functions of innate lymphoid cells (ILCs) and NK cell subsets are investigated thoroughly in cancer immunotherapy. ILC and recently described NK cell subsets in NSCLC patients’ blood samples and tumor draining lymph nodes were investigated. Methods. The study included chemotherapy and/or radiotherapy-naive NSCLC patients with clinical stage T1-4N0-2M0 who underwent video-assisted mediastinal lymphadenectomy and 14 healthy controls. Mononuclear cells were isolated from peripheral blood of both groups and mediastinal lymph nodes of NSCLC patients. NK cells and ILC subsets were analyzed by flow cytometry. Results. Total NK cells are shown to be increased in peripheral blood of NSCLC patients compared to lymph nodes while the ratio of CD56dimCD16- exhausted NK cells is higher in lymph nodes than in blood samples of NSCLC patients. Compared to control group, peripheral blood ILC1 cells were lower in NSCLC patients, however ILC2 and ILC3 cells were significantly increased. However, mediastinal lymph nodes of NSCLC patients had decreased ratio of ILC2 and increased ratio of ILC3 cells than in peripheral blood of patients. NSCLC patients had significantly increased ratio of NKp44-ILC3 cells and decreased ratio of NKp44+ILC3 in lymph nodes. Conclusion. Decreased ratio of ILC1 cells is an important indicator of impaired anti-tumoral response. Increased in the ratio of NKp44-ILC3 cells in NSCLC patients may potentially contribute to tumor progression. These findings highlight the distinct roles of ILCs, which play a pivotal role in the pathogenesis of lung cancer.

show abstract

“…The results of that study investigate whether quercetin targets the VEGF‐R2‐regulated AKT/mTOR/P70S6K pathway to prevent tumor and blood vessel development (Pratheeshkumar, Budhraja, et al, 2012). Lutein role was uncovered from in vitro and in vivo research approaches in PC‐3 cells, in addition to in LNCaP cell types, luteolin (10–40 M) suppresses angiogenesis as well as invasive by lowering the expressions of VEGF‐2R, androgen receptor (AR), as well as the PSA (Ahmed et al, 2023; Pratheeshkumar, Son, et al, 2012). Sanguinarine inhibits the phosphorylation of STAT3 at tyrosine 705 as well as serine 727.…”

Section: Mechanistic Approaches Of Natural Compounds Against Prostate...mentioning

confidence: 99%

The efficacy of natural bioactive compounds against prostate cancer: Molecular targets and synergistic activities

Mia,

Dey,

Sakib

et al. 2023

Phytotherapy Research

Self Cite

View full text Add to dashboard Cite

Globally, prostate cancer (PCa) is regarded as a challenging health issue, and the number of PCa patients continues to rise despite the availability of effective treatments in recent decades. The current therapy with chemotherapeutic drugs has been largely ineffective due to multidrug resistance and the conventional treatment has restricted drug accessibility to malignant tissues, necessitating a higher dosage resulting in increased cytotoxicity. Plant‐derived bioactive compounds have recently attracted a great deal of attention in the field of PCa treatment due to their potent effects on several molecular targets and synergistic effects with anti‐PCa drugs. This review emphasizes the molecular mechanism of phytochemicals on PCa cells, the synergistic effects of compound‐drug interactions, and stem cell targeting for PCa treatment. Some potential compounds, such as curcumin, phenethyl‐isothiocyanate, fisetin, baicalein, berberine, lutein, and many others, exert an anti‐PCa effect via inhibiting proliferation, metastasis, cell cycle progression, and normal apoptosis pathways. In addition, multiple studies have demonstrated that the isolated natural compounds: d‐limonene, paeonol, lanreotide, artesunate, and bicalutamide have potential synergistic effects. Further, a significant number of natural compounds effectively target PCa stem cells. However, further high‐quality studies are needed to firmly establish the clinical efficacy of these phytochemicals against PCa.

show abstract

Role of T cells in cancer immunotherapy: Opportunities and challenges

Cited by 39 publications

References 128 publications

Study of MDM2 as Prognostic Biomarker in Brain-LGG Cancer and Bioactive Phytochemicals Inhibit the p53-MDM2 Pathway: A Computational Drug Development Approach

Study of MDM2 as Prognostic Biomarker in Brain-LGG Cancer and Bioactive Phytochemicals Inhibit the p53-MDM2 Pathway: A Computational Drug Development Approach

The importance of alterations in innate lymphoid cell subsets in patients with non-small cell lung cancer and their role in tumorigenesis

The efficacy of natural bioactive compounds against prostate cancer: Molecular targets and synergistic activities

Contact Info

Product

Resources

About